Core Viewpoint - The stock of Qianxin Biopharmaceuticals-B (02509) has risen over 5%, reflecting positive market sentiment following the announcement of a significant licensing deal in the autoimmune sector [1] Group 1: Company Developments - Qianxin Biopharmaceuticals announced a licensing agreement with a subsidiary of Windward for the TSLPxIL-13 dual antibody drug, with a total potential value of up to $700 million [1] - This marks the third overseas transaction for Qianxin Biopharmaceuticals this year, following the global rights grant of QX030N to Caldera and the licensing of QX031N to Roche [1] Group 2: Market Position and Analyst Sentiment - Zhongyou Securities highlighted that the company is a leader in the domestic innovative drugs for autoimmune diseases, with a solid foundation in this field [1] - The company's mature pipeline is entering a monetization phase, enhancing its revenue-generating capabilities, while the successful overseas licensing deals provide further assurance for stable operations [1] - Huachuang Securities expressed optimism about the company's ability to maintain its leading position in the autoimmune sector [1]
港股异动 | 荃信生物-B(02509)涨超5% 三款长效双抗顺利出海 机构看好公司在自免领域领先地位